- Home
- SILC vs UNCY Comparison
SILC vs UNCY Comparison
Compare SILC & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILC | UNCY |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.6M | 145.3M |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SILC | UNCY |
|---|---|---|
| Price | $29.56 | $7.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | 41.1K | ★ 528.6K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | $17.17 | N/A |
| Revenue Next Year | $12.28 | $407.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.85 | $0.47 |
| 52 Week High | $29.61 | $7.57 |
Technical Indicators
Market Signals| Indicator | SILC | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 82.36 | 61.86 |
| Support Level | $17.75 | $5.95 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.56 | 0.41 |
| MACD | 0.71 | 0.06 |
| Stochastic Oscillator | 90.43 | 93.95 |
Price Performance
Historical ComparisonAbout SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.